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Abstract
Background: Pancreatic cancer has a five-year survival rate of ~8%, with characteristic molecular heterogeneity and
restricted treatment options. Targeting metabolism has emerged as a potentially effective therapeutic strategy for
cancers such as pancreatic cancer, which are driven by genetic alterations that are not tractable drug targets.
Although somatic mitochondrial genome (mtDNA) mutations have been observed in various tumors types,
understanding of metabolic genotype-phenotype relationships is limited.
Methods: We deployed an integrated approach combining genomics, metabolomics, and phenotypic analysis on a
unique cohort of patient-derived pancreatic cancer cell lines (PDCLs). Genome analysis was performed via targeted
sequencing of the mitochondrial genome (mtDNA) and nuclear genes encoding mitochondrial components and
metabolic genes. Phenotypic characterization of PDCLs included measurement of cellular oxygen consumption
rate (OCR) and extracellular acidification rate (ECAR) using a Seahorse XF extracellular flux analyser, targeted
metabolomics and pathway profiling, and radiolabelled glutamine tracing.
Results: We identified 24 somatic mutations in the mtDNA of 12 patient-derived pancreatic cancer cell lines
(PDCLs). A further 18 mutations were identified in a targeted study of ~1000 nuclear genes important for
mitochondrial function and metabolism. Comparison with reference datasets indicated a strong selection bias
for non-synonymous mutants with predicted functional effects. Phenotypic analysis showed metabolic changes
consistent with mitochondrial dysfunction, including reduced oxygen consumption and increased glycolysis.
Metabolomics and radiolabeled substrate tracing indicated the initiation of reductive glutamine metabolism and
lipid synthesis in tumours.
Conclusions: The heterogeneous genomic landscape of pancreatic tumours may converge on a common
metabolic phenotype, with individual tumours adapting to increased anabolic demands via different genetic
mechanisms. Targeting resulting metabolic phenotypes may be a productive therapeutic strategy.
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Background
Pancreatic cancer has one of the worst survival rates,
with fewer than 8% of patients surviving 5 years post-
diagnosis [1]. A near universal feature of pancreatic can-
cer, and one of its earliest molecular changes, is a consti-
tutively activating oncogenic KRAS mutation [2–5]. Along
with established roles in driving cell proliferation and
survival, KRAS and several other oncogenes (e.g., AKT)
and tumour suppressors (e.g., TP53), have recently been
shown to regulate metabolic pathways in pancreatic
and other cancer cells [6–8]. These metabolic changes
include increased use of glutamine to support cell
growth and proliferation, increased NADPH/NADP+
ratio to maintain cellular redox state [9] and rewiring
anabolic glucose metabolism by inducing glucose up-
take and enhancing glycolysis [10].
The role of altered nutrient metabolism in cancer cells
has attracted significant renewed interest, both in under-
standing tumourigenesis and as a potential therapeutic
target [6, 11–13]. Tumour cells upregulate the produc-
tion of biosynthetic intermediates for the building of
new cells, while maintaining or even slightly increasing
ATP levels and energy production. Some of the emer-
ging hallmarks of cancer metabolism include, but are
not limited to use of opportunistic modes of nutrient ac-
quisition and use of glycolysis/TCA cycle intermediates
for biosynthesis and NADPH production [14]. Glycolytic
intermediates are shunted into auxiliary pathways, driv-
ing generation of nucleotides, lipids, amino acids, and
complex sugars [15–17]. Cancer cells also use comple-
mentary fuel sources (e.g., amino acids and fatty acids),
and proliferating cells have increased uptake of these
metabolic substrates to meet increased demands for
biosynthesis and energy production. For example, glu-
tamine can be used in place of glucose to fuel the TCA
cycle, sparing glucose for glycolytic biosynthesis of
cellular building blocks [18]. The mechanisms under-
lying these metabolic shifts in different cancer types are
not fully established, and are likely complex given the
highly integrated nature of genes and signalling path-
ways regulating metabolism [17]. Targeting metabolism
may be an effective therapeutic strategy for cancers that
are driven by genetic alterations that are not tractable
as direct drug targets [11, 19]. In the context of the
very high penetrance of KRAS mutations in pancreatic
cancers, targeting metabolic enzymes was effective in
treating KRAS-mutant tumours in pre-clinical lung
cancer models [12].
Mitochondrial dysfunction and mutations in mitochon-
drial genes have been implicated in shifting cellular
metabolism to a state favouring tumour proliferation
[20–22]. While cells completely devoid of mtDNA
(rho-0) have reduced tumorigenic and metastatic cap-
acity in mice [23, 24] and need to acquire mtDNA from
host cells to restore function and growth [25], partial
mitochondrial dysfunction is known to induces migra-
tion, invasion, and metastasis [24].
Accumulation of somatic mutations in the mitochon-
drial genome (mtDNA) have been observed in various
tumour types [26, 27], but common “driver” mutations
have not been clearly identified and a limited number of
studies have shown a direct role for specific mtDNA
mutations in tumourigenesis using mitochondrial cybrid
models [28, 29]. In short, there is limited understanding
of genotype-phenotype relationships, or how these
mutations precisely impact on mitochondrial function
and cellular metabolism. The availability of a cohort of
patient-derived cell lines (PDCLs) through the Australian
Pancreatic Cancer Genome Initiative (APGI) [30, 31]
presents a unique opportunity to directly study links
between genotype and phenotype in pancreatic cancer
(Fig. 1a). This study is the first to use patient derived cell
lines to connect genotype to phenotype in pancreatic
cancer by measuring metabolic function in the context
of somatic mutations.
Methods
Patient-derived xenograft (PDX) generation
Six-to-eight-week-old female NOD/SCID/IL2Rgamma-/-
(NSG) mice and athymic Balb-c-nude mice were used
for the establishment of the patient derived xenograft
(PDX) model. All mice were bred at the Australian Bior-
esources (ABR). PDX were generated using a modified
version of the methodology published [32–34]. Briefly,
surgical non-diagnostic specimens of patients operated
at the various APGI clinical sites were implanted sub-
cutaneously into three NSG and three Balb-c-nude mice
for each patient, with two small pieces per mouse (left
and right flank; engraftment stage). Once established,
tumours were grown to a size of 1500 mm3, at which
point they were harvested, divided, and re-transplanted
into further mice to bank sufficient tissues for experi-
mentation (first passage and second passage). After ex-
pansion, passaged tumours were excised and propagated
to cohorts of 40 mice or greater, which constituted the
treatment cohort (third passage). Utilisation of the NOG
mouse model, which is characterized by high immune
deficiency in this study has enabled establishment of a
significant cohort of PDXs (70) xenografts, with a high
rate of successful engraftment and propagation (76%,
data not shown).
Patient-derived cell line (PDCL) generation
The selected patient-derived cell lines (PDCL) used in
this study, named The Kinghorn Cancer Centre (TKCC)
lines, were established by plating and growing cells from
an enzymatically digested xenograft on a collagen matrix
for approximately 1 week prior to removal of fibroblasts
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from the mixture using flow cytometry with anti-mouse
CD140a-PE (BD Biosciences, USA) and anti-mouse
MHCI-H2KD antibody, eBiosciences, USA) (Pajic et al.,
manuscript in preparation). All cell lines were profiled
by short tandem repeat (STR) DNA profiling as unique
(CellBankaustralia.com).
Cell culture procedures
Human pancreatic ductal endothelial (HPDE) cells were
used as a normal pancreatic cell control [35]. These cells
were routinely cultured in keratinocyte serum-free (KSF)
medium supplemented by epidermal growth factor and
bovine pituitary extract (Gibco Life Technologies USA).
After patient-derived xenografts (PDX) were completed,
PDX-derived PDCLs were routinely cultured in condi-
tions specifically formulated for each individual cell line
(refer Additional file 1: Supplementary Methods). In the
generation of each cell line (as described in [4, 34],
different media, culture conditions, and levels of oxygen
(both normal culture conditions and low, 2% which is
physiologically close to the oxygen levels found in the
hypoxic centre of a tumour) were tested. In vitro growth
conditions were selected based on conditions resulting
in best cell growth through multiple passages and those
resulting in cell lines most closely resembling physio-
logical cells from the initial tumour.
Mitochondrial genome sequencing
Mitochondrial genomes of each cell line (PDCLs, HPDE
and HPDE-KRASG12V), along with matched normal DNA
from each patient, and tumour DNA where available, were
sequenced a modified version of the protocol described
by [36]. Briefly, two overlapping long-range PCR amplifi-
cations were performed, generating 7.2 Kb Amplicon 1
(spanning bp 12,256-3,005) using primers Amp1-F: 5′-
GGCTTTCTCAACTTTTAAAGGATA-3′ and Amp1-R:
5′-TGTCCTGATCCAACATCGAG-3′; and 9.7 Kb
Amplicon 2 (spanning bp 2,583-12,337) using primers
Amp2-F: 5′-CCGTGCAAAGGTAGCATAATC-3′ and
Amp2-R: 5′-TTACTTTTATTTGGAGTTGCACCA-3′.
Platinum Taq polymerase kit (Invitrogen) was used and
touchdown cycling was performed as follows: (1) 94 °C
for 3 min, then (2) 10 cycles of 94 °C for 30 s, 71 °C for
45 s (decrease by 1 °C per cycle), 68 °C for 8 min, then
(3) 25 cycles of 94 °C for 30 s, 61 °C for 45 s, and 68 °C
for 8 min, and finally (4) 68 °C for 5 min, 4 °C for
15 min, and 10 °C hold. PCR cleanup was performed
using 0.6 μl Exonuclease I, 3 μl SAP, 11.4 μl nuclease free
water, and 30 μl PCR product, incubated at 37 °C for
75 min, 80 °C for 20 min, then cooled to 4 °C. Sanger se-
quencing was performed using 43 internal sequencing
primers (refer Additional file 1: Supplementary methods)
using the two large amplicons as template.
c
0 
10 
20 
30 
40 
50 
60 
70 
80 
PDCL mtDNA PDCL nuclear Ref mtDNA Ref nuclear 
non-synonymous synonymous 
p<0.005
p<0.05
%
 to
ta
l m
ut
at
io
ns
PDCL
mtDNA seq
Seahorse
metabolomics
drug response
substrate utilisation
mitoexome Genotype
Phenotype
a
Tumour
PDX
b
tRNL
1
tR
N
S
tRNS
tRNW
tR
N
D
K
N
Rt
tRNQ
tR
N
T
tR
NV
tRNY
tRNA
tRNH
tRNN
tR
NR
C
YTB
tRNC
tRNE
tR
NG
tR
N
P tR
N
F
CO
X1CO
X
2
C
O
X3
A
T
P
6
A
T
P
8
ND
4L
R
N
R
1
RN
R2
tRNI
ND4
ND1
ND2
ND
3
ND5
ND6
p
o
o
L
D
02:13195del FS 
03
:C
31
0T
, C
31
1T
  
C
Cs
ni6728:30
03:15692delA
TA
04:T15873C
 
07
, 1
9:
30
9i
n
sC
 
07:G4971A
07:G
7211A
07:T
113
61C
 
07:T12731C 
07:G13579A
07:C14207A
07:C16092T 
09:C4137T 
09:16188insC 
10
:C
43
8T
 
15:G4560C 
16:G14686A
17:C6029T  
18:G
15557A
18:C16126T 
26:G12508A
Fig. 1 Mitochondrial genome (mtDNA) sequence analysis in pancreatic cancer PDCLs. a Schematic showing the approach used to map
genotype:phenotype relationships in pancreatic cancer. b Distribution of somatic mtDNA mutations (red lines, n = 24) in 12 pancreatic PDCLs,
showing strong bias towards variants in ETC complex I coding and control regions. ETC subunit coding regions are denoted by subunit (colour coded
by ETC complex). Position of tRNAs are noted, with ticks marking 500 bp intervals. c Strong selection for non-synonymous mutants in mtDNA and
1056 nuclear genes important for mitochondrial function and metabolism in pancreatic PDCLs compared with a reference survey of mitochondrial
variants in infantile mitochondrial disease (Calvo et al. [39]). Statistical comparisons performed using Chi-squared analysis
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mtDNA sequence chromatogram base calls, alignments
and variant calls were performed using Sequencher soft-
ware, with manual verification. Overlapping sequences
were aligned against the linearised revised Cambridge ref-
erence sequence (rCRS) starting at position 1. When over-
lapping sequences crossed the D-loop and position 1, we
ensured this sequence was represented at both ends of the
linearised sequence to cover all bases. mtDNA sequences
have been deposited in the European Nucleotide Archive
(ENA) with study accession number: PRJEB18798.
Nuclear genome sequencing
The Australian Pancreatic Cancer Genome Initiative
(APGI) undertook the prospective recruitment of a
cohort of early stage (non-metastatic), non pre-treated
pancreatic ductal adenocarcinomas. At the time of
surgery, primary tumour specimens are obtained, in
addition to matched normal tissue, from the duode-
num. High confidence somatic single nucleotide vari-
ants and small insertions and deletions were identified
from exome-capture sequencing using SOLiD v4 from
primary tumours as previously reported [31], or from
patient derived xenografts and cell lines, sequenced
using Illumina HiSeq 2000, using qSNP [37] and Pindel
[38], respectively, as described in [31].
For the identification of nuclear encoded mitochon-
drial genes that are mutated in pancreatic cancer, the
published list of 1034 genes [39], was supplemented
with 22 additional genes that have been implicated in
mitochondrial function (Additional file 1: Table S1).
These mixed gene symbols and aliases were updated to
official gene symbols using custom scripts leveraging
the org.Hs.eg.db and AnnotationDbi Bioconductor
packages, and NCBI mapping data obtained 4/9/2012.
Somatic mutation data from primary tumours were
used for 5/12 of the cell lines studied here [31], while
for the remaining 7/12 cell lines mutations were iden-
tified from HiSeq 2500 data comparing xenograft
versus normal (unpublished). Mutations are reported
for nuclear encoded mitochondrial genes in mutation
annotation format (MAF) file.
Cellular bioenergetics measurements
Cellular oxygen consumption rate (OCR) and extracellu-
lar acidification rate (ECAR) were measured with a Sea-
horse XF extracellular flux analyser (Seahorse Bioscience
Inc) according to the manufacturer’s instructions. Briefly,
cells were seeded in a Seahorse XF 24-well assay plate at
a cell density between 15,000 and 30,000 cells per well
in full growth medium. After overnight attachment, the
medium was washed and replaced with prewarmed
running medium (non-buffered DMEM supplemented
with 1 mM sodium pyruvate and 10 mM glucose, pH 7.4)
and incubated in a non-CO2 incubator at 37 °C for
60 min. Basal levels of OCR and ECAR were recorded for
24 min, followed by a mitochondrial stress test (1 μg/ml
oligomycin, 0.3 μM FCCP, 1 μM rotenone/1 μM anti-
mycin A) [40]. Cells were lysed post-measurement and
protein content estimated using BCA Assay (Pierce).
Metabolomics
Preparation of samples followed a modified version of
protocol described by [41], optimised for human cells.
Cells were quenched and washed with 0.9%w/v NaCl at
4 °C and metabolites were extracted by the addition of
cold 50% methanol. 20 μl of d4-alanine (Sigma-Aldrich)
was added to each sample (10 mM final) as an internal
control. Samples were subjected to four rounds of vor-
texing and freeze-thawing (−80 °C for ~30 min) before
centrifugation at 15,000 rpm for 15 min at -20 °C.
Supernatant was decanted and stored at -80 °C.
Remaining cell pellet was subjected to sequential metha-
nol extraction using 80 and 100% methanol, vortexing
and centrifugation as above. Extractions were pooled
and deionised water added to bring methanol concentra-
tion below 20% before being frozen at −80 °C and lyo-
philised. Analysis was focused on amino acids, organic
acids and fatty acids (Additional file 1: Table S3) using
20–25 mg of cell dry-weight per sample. Samples were
derivatised using methyl chloroformate and analysed by
gas chromatography–mass spectrometry (GC–MS) [41].
Pathway activity profiling (PAPi) was used to compare
metabolic pathway activities from metabolic profiles
[41, 42]. Samples were normalised by the abundance of
internal standard (2,3,3,-d4-alanine) and biomass con-
tent (Additional file 2: Table S4). Activity scores were
assigned to each pathway, based on the number and
abundance of the relevant metabolites identified within
the samples of this study. Partial least squares discrim-
ination analysis (PLS-DA) of all pancreatic cell lines
was performed using Multibase (http://www.numerical
dynamics.com). ANOVA, Tukey’s HSD and hierarchical
clustering were performed to determine which pathways
were activated or attenuated in PDCLs compared with
HPDE. Heat map representations of the results were
produced by ggplot2 R packages [43].
Radiolabelled glutamine tracing
The rate of conversion of glutamine to lipid was measured
by incubating PDCLs in DMEM containing 2% BSA,
5 mM glucose, 0.5 mM oleate, 0.5 μCi/ml 14C L-
glutamine, 2 mM L-glutamine and 1 mM carnitine for
4 h. Cells were rinsed in PBS and lipids extracted in
chloroform:methanol (2:1 v:v). Following centrifugation
(1000 g for 10 min) the organic phase was evaporated
to dryness under nitrogen gas at 40 °C and radiation
measured by scintillation counter (1900CA Tri-Carb
Liquid Scintillation Analyzer, Packard).
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Results
Novel somatic mitochondrial DNA mutations in
pancreatic PDCLs
While extensive genomic profiling of pancreatic cancer
has been performed by us and others [4, 5, 31, 44–46],
these analyses did not report mtDNA sequences. Hence,
mtDNA sequencing in twelve PDCLs and matched nor-
mal DNA from each patient in the APGI cohort [31]
identified 24 somatic mutations (Fig. 1b and Table 1).
Significantly, these mutations occurred mainly in coding
regions of ETC Complex I and control regions, and the
majority of coding region variants observed were non-
synonymous. Comparison with MitoMap [47] indicates
that most of the mutations identified have not been pre-
viously described, particularly in a cancer context.
All PDCLs sequenced (based on availability of matched
normal DNA for comparison) had at least one mutation
present, with eight mutations in TKCC-07. While the
same base pair mutation was not observed repeatedly,
multiple mutations were found in common ETC subunits
across different cell lines. Most mutations identified were
either non-synonymous, and predicted to result in amino
acid changes (11/24, 46%) or located in control regions
(10/24, 42%). Only 12.5% (3/24) of mtDNA mutations
were synonymous or silent mutations. Comparison with a
reference survey of mitochondrial variants in infantile
mitochondrial disease [39] indicates that there is a very
strong positive selection bias for non-synonymous variants
in coding regions of the mtDNA in pancreatic tumours
(Fig. 1c).These data are strongly suggestive of positive
selection bias for mutations causing functional effects via
amino acid changes or transcriptional control)
The majority of somatic mtDNA mutations in PDCLs
(summarised in Fig. 1b) were observed in ETC complex I
subunits (n = 9), and noncoding control regions (n = 10)
such as the hypervariable segments located in the D-loop,
NC7, L promoter, and tRNA glutamic acid. Somatic muta-
tions were distributed across five of the seven complex I
subunits that are encoded by the mtDNA. Somatic mu-
tations were also seen in cytochrome C oxidase subunit
Table 1 Somatic mtDNA mutations identified in 12 PDCLs
Cell line ChrM position Normal Tumour Cell line AA change Region ETC complex Literature
TKCC-02 13,195–14,000 cons 2 bp del 2 bp del Frameshift ND5 I Similar region- colorectal cancer:
Polyak 1998
TKCC-03 310 C/T T T - HVSII -
311 C/T C C - HVSII -
8276.3–8276.4 CC ins :: :: - NC7 -
15,692–15,694 ATA ::: del ::: del M316Δ CytB III T15693C LVNC cardiomyopathy:
Tang 2010
TKCC-04 15,873 T - C/T M376T CytB III NOVEL
TKCC-07 309.3 : - C ins - HVSII - Alzheimer’s: Tanaka 2010
4971 G - A G168S ND2 I NOVEL
7211 G - A M436M COI IV
11,361 T - C M201T ND4 I
12,731 T - C V132A ND5 I NOVEL
13,579 G - A A415T ND5 I NOVEL
14,207 G (C reverse) - A
(T reverse)
T156I ND6 I
16,092 C - T - HVSI -
TKCC-09 4137 C T T Y277Y NDI I
16,188.1 : : C ins - HVSI -
TKCC-10 438 C C/T T - L strand promoter -
TKCC-15-LO 4560 G - C/g W30S ND2 I NOVEL
TKCC-16-LO 14,686 G - G/a - TE (tRNA) - NOVEL
TKCC-17-LO 6029 C - T/c G42G COI IV
TKCC-18-LO 15,557 G - A Q271K CytB III NOVEL
16,126 C - T
(wt ref. seq)
- HVSI - Glioblastoma T > C Kirches 2001,
Brandon 2006
TKCC-19-LO 309.1–309.2 C CC CC - HVSII -
TKCC-26-LO 12,508 G - A P58N ND5 I NOVEL
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I (COI of complex IV (n = 2)) and cytochrome B (CyB)
of complex III (n = 3).
In a few rare cases, DNA samples from the original
tumour were available, and corresponded with the se-
quence of the tumour cell lines. For example, TKCC-09
and TKCC-19-LO had mutations in both the tumour
and tumour cell line. Of the 24 cell line mutations, 4
were heteroplasmic and 20 were homoplasmic. One
interesting example is TKCC-03, where both tumour
and cell line were homoplasmic for T and C at bp 310
and 311 respectively, but matched normal tissue was
heteroplasmic at these sites (i.e., both C and T were
present at each site). In TKCC-10, heteroplasmy was
observed in the tumour at base pair 438 (C/T) while
the cell line was homoplasmic for this mutation (C > T)
(Additional file 1: Figure S1). This could indicate either
improved tumour cell purity in the genetic sample
from the PDCL, the presence of contamination of nor-
mal tissue in the surgical tumour sample, or positive
selection for the mutation under culture conditions.
Heteroplasmy was also observed in TKCC-15-LO, -16-
LO, and -17-LO, with levels of the mutant higher than
the wild type sequence in all cases. TKCC-02 harbours
a deletion resulting in a frameshift mutation in a region
of ND5 (Complex I), which has been implicated in
colorectal cancer [48]. Interestingly, mtDNA sequence
of a liver metastasis from the patient corresponding to
TKCC-19-LO showed that the metastasis had the iden-
tical sequence as the original tumour, with the same
somatic mutation (chrM:g.3091-3092insC). Of note, no
mutations were detected in the mtDNA of HPDE after
extended culture following transfection with mutant
KRAS (G12D).
Functional effects of somatic mtDNA mutations predicted
by molecular modelling
To predict functional effects of non-synonymous muta-
tions, molecular modelling was performed using a hu-
man homology model of the structure of ETC complex
I (based on PDB entry 4HEA) [49] (Table 2). All muta-
tions were located in the membrane domain of the
complex, and were predicted to affect complex assem-
bly (due to stability and protein folding issues), enzyme
activity, and/or proton leakage. Modelling was also
performed on ETC complex III mutations (bovine
model, PDB entry 2FYU) [50], with predicted effects on
its cytochrome B subunit including possible changes in
redox capacity (Table 2).
Somatic nuclear mutations implicated in mitochondria
and metabolism
As part of the APGI project, nuclear genome sequence
data for the PDCL cohort was also available [4, 5, 31].
Calvo et al. previously created a comprehensive list of
1034 nuclear genes encoding mitochondrial proteins, as
part of the “Mitoexome” in their study of infantile
mitochondrial disease [39]. These genes, along with 22
additional genes that have been implicated in metabolic
function, were analysed for somatic mutations in pri-
mary tumours corresponding to PDCLs (complete list of
genes analysed is provided in Additional file 1: Table S1).
In addition to mtDNA mutations, a total of 18 somatic
Table 2 Predicted effects of mutations in ETC subunits
ETC subunit PDCL Mutation Predicted effect
Complex I human residues (corresponding Thermus thermophilus residues)
ND5 TKCC-02 Frameshift Part of ND5 loss, therefore no active complex I
TKCC-07 V132A (V119) V sits at the end of TM4 and faces TM3, may slightly destabilise fold in this area.
TKCC-07 A415T (V409) A sits on TM13, facing TMs 9 and 10, may de-stabilise fold in this area and/or make channel
cavity leaky in this area.
TKCC-26-LO D58N (F55) D sits on the beta-sheet from the beta-H motif, may interfere with conformational coupling.
ND4 TKCC-07 M201T (L199) M sits on key flexible helix 7 and faces the lipid or supernumerary subunit, may interfere with
mechanics of TM7 and decrease NADH:Q oxidoreductase activity and/or proton pumping.
ND2 TKCC-07 G168S (A247) Directly facing traverse helix HL from ND5, might decrease NADH:Q oxidoreductase activity
(or proton pumping only) preventing full movement of HL.
TKCC-15-LO W30S (L108) W provides part of a seal between ND2 and ND4L, therefore mutation might make it somewhat
leaky to protons.
ND6 TKCC-07 T156I (V142) T is near key ND2 Glu34 (GluTM5), so the mutation may interfere with its pKa and so with proton
pumping through ND2. Fold in this area will also be disturbed.
Complex III (bovine model 2FYU)
CytB subunit TKCC-03 M316Δ May interfere with fold at the junction with subunit 6.
TKCC-04 M376T Leu in bovine- peripheral, but may interact with N-term helix from subunit 7.
TKCC-18-LO E271K E in bovine- close to heme (6 A, directly facing the edge), so may well interfere with its redox properties.
TM transmembrane, ND NADH dehydrogenase subunit, CytB cytochrome B
Hardie et al. Cancer & Metabolism  (2017) 5:2 Page 6 of 15
nDNA mutations were discovered in this targeted mito-
chondrial/metabolic gene set (in 16 genes, 2 were in
TP53 and 2 in ADCK4) (Table 3). Notably, mutations
were not observed in nuclear-encoded ETC subunits.
Consistent with the genetic pathology of pancreatic can-
cer, all patient samples also had somatic KRAS mutations
[3]. As observed for mtDNA mutations, comparison with
mitochondrial variants in infantile mitochondrial disease
[39] indicated strong positive selection bias for non-
synonomous variants (Fig. 1b).
Somatic mutations were identified in several key genes
involved in metabolism (Table 3 and Additional file 1:
Table S2). These include two enzymes in fatty acid me-
tabolism: Acetyl Co-A carboxylase (ACACA), involved
in the rate limiting step of fatty acid synthesis and carni-
tine palmitoyltransferase I (CPT1C), an acetyltransferase
which transports long chain fatty acids across the outer
mitochondrial membrane. Mutations were also found in
pyruvate dehydrogenase alpha 2 (PDHA2) which cataly-
ses oxidative decarboxylation of pyruvate as well as lac-
tate dehydrogenase B, catalysing reversible conversion
of lactate to pyruvate. While some PDCLs contain few
somatic mutations in mtDNA and several in nuclear
DNA (e.g., TKCC-04 and TKCC-09), TKCC-07 had no
nDNA mutations but many in the mtDNA. In sum-
mary, there is a possibility for mixed effects of mtDNA
and nuclear mutations.
Metabolic phenotype of pancreatic tumour cell lines
Mitochondrial and glycolytic stress tests were performed
to measure oxygen consumption rate (OCR) and extracel-
lular acidification rate (ECAR) of PDCLs, as approximates
of mitochondrial respiration and glycolysis, respectively.
Human pancreatic ductal epithelial (HPDE) cells were used
as a control as they are the closest available to the normal
cells from which pancreatic tumours in this study were
derived [35, 51–53]. Comparing overall metabolic profiles
(OCR vs ECAR) for 16 tumour cell lines and HPDE control
cells (Fig. 2) showed that PDCLs have relatively lower OCR
and higher ECAR. This is consistent with the concept of
aerobic glycolysis (Warburg effect) in tumour cells, with in-
creased ECAR indicating higher glycolytic flux. Lower OCR
in PDCLs indicates attenuated oxidative phosphorylation in
these cells. In the context of somatic mtDNA mutations in
these cells, this effect most likely reflects defects in mito-
chondrial respiration. Notably, those PDCLs harbouring
mutations in ETC complex I (TKCC-02, TKCC-07, TKCC-
09, TKCC-15-LO, TKCC-26-LO), complex III (TKCC-03),
Table 3 Somatic nuclear DNA mutations in nuclear encoded mitochondrial and metabolic genes in TKCC pancreatic tumours (n = 12)
Cell line Gene Chrom Position Variant Class Ref.
Allele
Tumour
Allele 1
Tumour
Allele 2
dbSNP RS Normal
Allele 1
Normal
Allele 2
Bp change AA change
TKCC-02 TRIT1 1 40319722 Nonsense G A G novel G G G > A R112*
TKCC-03 None detected
TKCC-04 MRPS21 1 150266837 Silent G C G novel G G 113G > C G17G
TP53 17 7578406 Missense C T T rs28934578 C C 524C > T R175H
ACACA 17 35615179 Missense C A C novel C C 2099C > A R539S
CPT1C 19 50203981 Missense G A G novel G G 694G > A A108T
PIK3CA 3 178952085 Missense A A T rs121913279 A A 3297A > T H1047L
PDHA2 4 96761551 Missense T C T novel T T 313 T > C F84L
TKCC-07 None detected
TKCC-09 AKT3 1 243736250 Missense T C T novel T T 863 T > C K266R
YME1L1 10 27437884 Missense T G T novel T T 301 T > G Q40P
ADCK4 19 41208536 Missense G A A novel G G 1164G > A R288C
TKCC-10 None detected
TKCC-15-LO MTCP1 X 154293944 Missense G A G novel G G G > A R76C
TKCC-16-LO HMGCL 1 24143254 Missense C A C novel C C 303C > A D87Y
ADCK4 19 41198257 Missense C C G novel C C 1620C > G E440Q
AGXT2 5 35013131 Silent C C T novel C C 1317C > T A327A
TKCC-17-LO TP53 17 7578553 Splice Site T C C novel T T 377 T > C Y126C
TKCC-18-LO TARS2 1 150477113 Missense C C T novel C C C > T A575V
TKCC-19-LO None detected
TKCC-26-LO LDHB 12 21788484 Missense C A C novel C C C > A D333Y
ADSL 22 40676075 Silent G A G novel G G G > A
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or complex IV (TKCC-07, TKCC-17-LO) showed the
largest attenuation of oxygen consumption relative to
HPDE, supporting the predicted functional effects of
somatic mtDNA mutations on ETC function (Table 2).
Metabolomic profiling of pancreatic cancer PDCLs
We deployed a targeted metabolomics approach to de-
termine changes in metabolic flux of pancreatic cancer
PDCLs using a list of 72 metabolites representing major
metabolic pathways (Additional file 1: Table S3). Relative
abundance of each metabolite was determined following
normalisation to protein content. Partial Least Squares
Discrimination Analysis (PLS-DA) of metabolite profiles
of each of the 13 PDCLs and normal HPDE cells (Fig. 3a)
showed that normal pancreatic cells (HPDE) clustered
away from tumour cell lines. Interestingly, when HPDE
cells were grown in a more enriched tumour media
(M199/F12 plus additives (described in Additional file 1:
Supplementary methods), their metabolic profile appeared
closer to - but still distinct from - those of PDCLs. Inter-
estingly, HPDE cultured in M199/F12 also adopted a more
mesenchymal morphology (not shown). Three distinct
groupings of different PDCLs were apparent, suggesting
similarity in metabolite profiles between individual tu-
mours in each of these groups. All PDCLs cultured in low
oxygen (TKCC-15-LO, -16-LO, -17-LO, -19-LO, -26-LO)
were clustered together, along with TKCC-05, TKCC-10,
and TKCC-06. Further, two PDCLs harbouring mutations
in ETC complex III (TKCC-03 and TKCC-18-LO) formed
a distinct cluster. Importantly, PDCLs did not cluster
based on the culture media they were grown in, suggesting
that differences in metabolite profiles were not strongly
influenced by differences in media composition.
Hierarchical clustering of individual metabolite profiles
across all cell lines including HPDE (Fig. 3b) revealed
five main groupings. As observed in PLS-DA analysis,
HPDE cells grown in KSFM media had distinctly different
metabolite profiles from tumour cell lines, with TKCC-03
and TKCC-18-LO (both harbouring complex III muta-
tions) forming distinct branches. Other tumour cell
lines clustered quite closely together, with two main
subgroups apparent.
When abundance of intracellular metabolites was
expressed relative to levels in HPDE cells, a number of
differences in key metabolites were observed (Fig. 3c).
Metabolites that were significantly different across cell
lines are coloured red (higher) and blue (lower), while
white indicates no significant change (using ANOVA
and Tukey’s HSD analysis). There is no clear grouping of
PDCLs in line with mtDNA mutational spectra or cul-
ture media. However, five main metabolite clusters were
apparent. The first, comprising cysteine, tyrosine, and
palmitic acid was significantly more abundant in PDCLs
compared to normal HPDE cells. A second cluster con-
taining a number of fatty acids was also significantly
more abundant in most tumour cell lines. There was a
significant cluster of metabolites that were significantly
less abundant in PDCLs. Notably, succinate abundance
was significantly higher in both TKCC-03 and TKCC-18-
LO (Fig. 3d), which harbour non-synonomous somatic
mutations in CytB (ETC complex III) (Table 1). This effect
is entirely consistent with disrupted CytB activity in these
cells, which would be expected to impede the conversion
of succinate to fumarate. Mullen et al. [54] have previously
observed high levels of succinate in cells with ETC com-
plex III mutations using reductive carboxylation.
The flux of metabolites through their respective path-
ways is key in understanding the role they play in cancer
metabolism and the overall metabolic needs of the cancer
cell. To predict which metabolic pathways were dysregu-
lated in pancreatic tumour cells, we performed Pathway
Activity Profiling (PAPi) analysis of metabolomics data
[42]. Pathway activity scores calculated using this method
have been shown to be an accurate predictor for metabolic
flux [55], even though there may be redundancy between
metabolites, with some being key in several pathways. Ac-
tivity scores were compared between different cell lines
and different growth media conditions and formed the in-
put for hierarchical clustering (Fig. 4). ANOVA was used
to determine pathways with significantly different activity
(p < 0.05) in PDCLs.
Pathway analysis parsed PDCLs into 5 distinct clusters
(Fig. 4a). Interestingly, TKCC-02, TKCC-07, and TKCC-
09, which all harbour somatic non-synonymous complex
I mutations formed a very distinct cluster based on
metabolic pathway activity. Three main groupings of
metabolic pathways were observed. The first contained
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pathways that were significantly overrepresented in
most of the tumour cell lines. These include several key
pathways with potentially important roles in cancer
(i.e., biosynthesis, signalling, immunity, etc.) including
phenylalanine, tyrosine, and tryptophan biosynthesis;
fatty acid metabolism; fatty acid elongation; sphingolipid
metabolism (important in biological membranes); eicosa-
noids (fatty acid-derived signalling molecules important in
inflammation and immunity, e.g., prostaglandins) along
with its precursor arachadonic acid metabolism; and ster-
oid degradation. Consistent with the Warburg effect, the
second branch indicated that glycolysis was upregulated
in most of the tumour cell lines. The final branch includes
downregulated pathways in the tumour cell lines relative
to normal HPDE. Notably, oxidative phosphorylation
was significantly attenuated in PDCLs, consistent with
mitochondrial dysfunction caused by the somatic mtDNA
mutations detected in PDCLs. Other downregulated
pathways included D-Arginine and D-ornithine metabol-
ism; ubiquinone and other terpenoid-quinone biosyn-
thesis; and pyruvate metabolism. No consistent effects of
either media type or oxygen levels during incubation
were observed on clustering.
Radiolabelled glutamine tracing
Metabolomics analysis strongly indicated upregulated
fatty acid synthesis in pancreatic PDCLs (Fig. 4a) and
using radiolabelled glutamine tracing we observed
significant conversion of glutamine to lipid in these
cells (Fig. 4b). Significantly, relatively higher conver-
sion of glutamine to lipid was observed in PDCLs
cultured under hypoxic conditions (i.e., TKCC-15-LO,
-16-LO, -18-LO, -19-LO, -26-LO). These effects are
consistent with previous observations of reductive
carboxylation in cells with mitochondrial defects [54],
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and glutamine dependence in pancreatic tumours
with KRAS mutations (Fig. 4c) [9].
Discussion
A feature of pancreatic cancer, and one of its earliest
molecular changes, is a constitutively activating onco-
genic KRAS mutation [2, 3]. KRAS signalling in cancer
drives cell proliferation and promotes survival. In
pancreatic cancer cells, KRAS, along with several other
oncogenes (e.g., AKT) and tumour suppressors (e.g.,
TP53), have been shown to regulate metabolic path-
ways Jones and Schulze [6]. These metabolic changes
include elevated partitioning of glucose carbons to bio-
synthetic pathways, increased use of glutamine to sup-
port growth, and increased NADPH/NADP+ ratio to
prevent oxidative damage from reactive oxygen species
(ROS), maintain cellular redox state, and for use in bio-
synthesis [9]. Mutant Kras copy number has also been
shown to result in metabolic reprogramming in vivo in
a mouse model of lung cancer, with increased channel-
ling of glucose-derived metabolites into the TCA cycle
and glutathione biosynthesis [56]. Understanding the
mechanistic basis of these metabolic alterations and
their role in tumourigenesis is the focus of intense
interest. [6, 11–13] Targeting metabolism as an effector
of oncogenic signal transduction pathways required for
cell growth may be an effective way of treating cancers
that are driven by genetic alterations that are not tract-
able as direct drug targets [11, 19]. Of direct interest to
pancreatic cancers, which have very high penetrance of
KRAS mutations, targeting metabolic enzymes has been
shown to be effective in treatment of KRAS mutant
tumours in pre-clinical models of lung cancer [12].
Mitochondria are the primary site for energy gener-
ation within cells and are regulated by interplay between
the nuclear and mitochondrial genomes. The mitochon-
drial genome (mtDNA) encodes 37 genes, including 13
subunits of the mitochondrial electron transport chain
(ETC). Mitochondrial dysfunction and/or mutations in
mitochondrial genes may play a role in shifting cellular
metabolism to a state more favourable for tumour prolif-
eration [20, 21]. Accumulation of somatic mtDNA muta-
tions has been observed in various tumour types [26, 27]
and a limited number of studies have shown a direct
role for specific mtDNA mutations in tumourigenesis
using mitochondrial cybrid models [27–29, 57]. There
is evidence that mtDNA mutations affect respiratory
complex assembly [58, 59] but in the cancer context,
there is limited understanding of genotype-phenotype
relationships, or how these mutations precisely impact
on mitochondrial function and overall cellular metabol-
ism. Somatic mtDNA mutations have been identified in
almost all human cancers, including pancreatic cancer
[22, 26, 27]. While earlier studies suggested somatic
mutations occur by chance and are likely neutral, more
recent evidence suggests these mutations are likely
tumourigenic [60]. A 2009 study described mtDNA
mutations that alter ROS generation and apoptosis [61]
and a 2010 review of 33 studies for 1227 tumour samples
reported 50% to carry potentially tumourigenic somatic
mtDNA mutations [62].
We identified numerous novel mutations in mtDNA-
encoded subunits of the electron transport chain (ETC)
in pancreatic cancer (Table 1), with several novel muta-
tions also identified in nuclear encoded mitochondrial
genes (Table 3). These mutations were somatic—that is,
they were not inherited or found in matched normal
tissues but we cannot exclude the possibility that some
mtDNA mutations arose secondary to PDCL culture
conditions. Every patient cell line tested had at least one
mutation, with most harbouring multiple mutations.
The majority of the mutations identified were predicted
to have a functional effect, either by causing a change
in an amino acid coding (the majority located in ETC
complexes I, III, or IV), or due to presence in a control
region of DNA (Table 2, Fig. 1b). These data are
strongly suggestive of positive selection bias for somatic
mutations causing functional effects via amino acid
changes or transcriptional control (Fig. 1c). Strikingly,
we did not observe any somatic mutations in nuclear-
encoded ETC subunits across the tumour cohort.
Given the critical role of mitochondria in metabolism,
these somatic mutations in tumour cells may be import-
ant drivers of deregulated tumour metabolism. This
characteristic shift towards increased biosynthesis and
aerobic glycolysis, and often a decrease in oxidative me-
tabolism, has been described in other cancers, such as
breast cancer [63], but its cause(s) are currently not well
described. While other studies have identified somatic
mtDNA mutations in cancers [22, 27, 64, 65], in many
cases, the functional effects of these variants has not
been well characterised. This study is the first to use pa-
tient derived cell lines to connect genotype to phenotype
in pancreatic cancer by measuring metabolic function in
the context of somatic mtDNA mutations.
Somatic variants identified in mitochondrial ETC and
metabolic genes in pancreatic tumours were associated
with functional effects on metabolic phenotype. Seahorse
analysis showed overall decreased oxidative metabolism,
and increased glycolysis in all PDCLs (Fig. 2). In particu-
lar, PDCLs harbouring non-synonomous mutations in
mtDNA ETC complex I genes showed the highest de-
creases in oxygen consumption (Fig. 2). Mitochondrial
mass was previously shown to be increased in metastatic
breast cancer [66, 67]. However, measurement of mito-
chondrial abundance in pancreatic cancer cell lines
using flow cytometry showed similar mitochondrial
levels across various cell lines (not shown), suggesting
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that any observed phenotype effects were due to muta-
tions or expression differences in mitochondrial and
metabolic genes between cell lines, rather than bulk
differences in mitochondrial number.
The apparent heterogeneity of mutations in mtDNA
is consistent with that observed in the nuclear genome
of pancreatic cancer [31]. However, our data suggest
that mitochondrial mutations or genotypes may be
categorised into only relatively few metabolic pheno-
types. In other words, mutations in different base posi-
tions but with similar functional consequences (e.g.,
complex I dysfunction) exist. Mutations within the
same mtDNA gene have previously been shown to re-
sult in similar subunit assembly profiles [68]. In
addition, a targeted list of over a thousand nuclear-
encoded genes encoding mitochondrial proteins and
key metabolic proteins was studied in the TKCC pa-
tients. This analysis revealed 18 novel somatic muta-
tions across 12 PDCLs. Nearly all of these mutations
resulted in amino acid changes (Table 3) in well-known
metabolic genes such as LDHB (which is important in
glycolysis for the conversion of lactate and pyruvate),
TRIT1, which has been proposed as a tumour suppres-
sor [69] and CPT1C, important in fatty acid metabol-
ism. Hence, it is highly likely that mutations in nuclear
mitochondrial and metabolic genes are acting in con-
cert with mtDNA mutations to contribute to the meta-
bolic phenotype in pancreatic tumours.
Metabolomics analysis showed some clear common ef-
fects in tumours when compared to normal cells (Fig. 3).
A recent study used metabolite profiling in concert with
gene expression to identify three metabolic subtypes of
pancreatic cancer (reduced proliferation, glycolytic, and
lipogenic) [70], but a limitation of this study was that
it used only cell lines and somatic mutations were not
investigated. Overall, there were larger differences
between normal cells and tumours than between indi-
vidual tumours, but variance was also evident between
tumours. Three distinct groupings of PDCLs were appar-
ent, suggesting similarity in metabolite profiles between
individual tumours in each of these groups. For example,
all PDCLs cultured in low oxygen clustered together. Fur-
ther, two PDCLs harbouring mutations in ETC complex
III (TKCC-03 and TKCC-18-LO) formed a distinct clus-
ter. Notably, significantly increased levels of succinate
were observed in these lines, as has previously been ob-
served for other tumours harbouring ETC complex III/IV
mutations [54]. Importantly, PDCLs did not cluster based
on different culture media used, suggesting that differ-
ences in metabolite profiles were not strongly influenced
Fig. 5 Proposed convergence model of mtDNA mutations driving metabolic adaptation in pancreatic cancer. We propose a model in which the
underlying nuclear genomic landscape of pancreatic cancer cells induces a metabolic challenge. As an adaptation to increased biosynthetic
requirements, tumours attenuate oxidative phosphorylation through positive selection for diverse somatic mitochondrial mutations, which
converge on common metabolic phenotypes
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by differences in media composition. While changes to in-
dividual amino acid abundance in PDCLs are generally
consistent with previous observations in murine PDAC
[71], it should be noted that tumours from engineered
mice with defined, homogeneous genetic background
would not necessarily capture the characteristic hetero-
geneity of human PDCLs used in our study.
Changes in several noteworthy metabolites between
normal and tumour cells were identified in metabolomics
analysis, implicating activation of reductive carboxylation in
pancreatic tumours with mitochondrial mutations. Mullen
et al. [72] showed that proliferating malignant prostate can-
cer cells with complex I or complex III mutations, or even
normal mitochondria targeted by other pharmacological
mechanisms of inhibiting ETC, were dependant on glutam-
ine as their major source of citrate formation and lipogenic
precursor production via reductive rather than oxidative
metabolism. These cells are able to use isocitrate dehydro-
genase (IDH) to convert α-ketoglutarate to isocitrate, which
can then be converted to citrate, and then Acetyl-CoA used
in fatty acid and lipid synthesis. Both fatty acid and lipid
synthesis are key biosynthetic pathways in cancer prolifera-
tion [13, 73] and our pathway analysis (Fig. 4) indicated in-
creased fatty acid synthesis pathways in tumour cells. In the
context of mtDNA mutations described above, these
metabolomics data are consistent with the activation of re-
ductive carboxylation in the pancreatic tumours studied.
Indeed, our observation of conversion of glutamine to lipid
in pancreatic PDCLs, and its upregulation in hypoxic con-
ditions (Fig. 4) further supports this assertion. However, we
cannot exclude the possibility that glutamine may be pro-
viding carbon for lipogenic citrate through its canonical
oxidation via the TCA cycle.
Hence, we propose a model whereby pancreatic tu-
mours attenuate mitochondrial oxidative phosphoryl-
ation through positive selection for various somatic
mitochondrial mutations, initiating reductive glutamine
metabolism to promote the production of biosynthetic
intermediates to support cell proliferation (Fig. 5). These
observations are consistent with recent gene expression
analyses in various cancer types, which indicate that can-
cer cells converge towards common metabolic landscapes
(including downregulation of mitochondrial pathways) via
different genetic mechanisms in cancer evolution [74, 75].
That is, there may be positive selection for attenuation of
ETC function in pancreatic tumours as an adaptation
to increased biosynthetic requirements, consistent with
the recently proposed evolutionary model of pancreatic
cancer [8]. In this context, it is interesting to note the
increased risk of pancreatic cancer associated with dia-
betes and obesity and that the anti-diabetes drug met-
formin increases the dependency of prostate cancer
cells with normal ETC function on reductive glutamine
metabolism [76].
Conclusions
Previous studies have implicated mutations or altered
expression in individual enzymes, or alterations in spe-
cific signalling pathways (e.g., PI3K, AKT or mTOR) in
driving the metabolic adaptations observed in a variety
of cancers [16, 17, 77–79]. In contrast, we propose a
highly novel mechanism for the metabolic shift observed
in pancreatic tumours. In short, the heterogeneous
genomic landscape of pancreatic tumours may con-
verge on a common metabolic phenotype, with individ-
ual tumours adapting to increased anabolic demands
via different genetic mechanisms (Fig. 5). Hence, targeting
common phenotypic traits, rather than specific genetic
lesions, may be a productive therapeutic strategy in
pancreatic cancer.
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